Bioventus Overview
Valuation check: BVS's P/E ratio is 31.11, above the Healthcare sector average of 27.22.
Get informed when a big investor buys or sells
+ Follow31.11
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for BVS is 31.11. That is above the Healthcare sector average of 27.22. Investors often review this figure alongside Bioventus's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, BVS currently prints 31.11 for P/E ratio, while the sector average sits near 27.22. That is roughly 14.3% above the sector mean. Large gaps often invite a closer look at Bioventus's growth, margins, and balance sheet.
A P/E ratio of 31.11 for Bioventus is not 'good' or 'bad' on its own. Compare it with the peer average (27.22) and with BVS's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting BVS's P/E ratio (31.11), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Bioventus's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
